Literature DB >> 2785560

Low natural antibody and low in vivo tumor resistance, in xid-bearing B-cell deficient mice.

D A Chow1, R D Bennet.   

Abstract

Evidence from correlative studies and Winn-type assays in syngeneic murine models has suggested that natural antibodies contribute to resistance against tumors in vivo. The B cell deficit associated with the X-linked immunodeficiency of CBA/N strain mice provided a genetic model in which to further test this question. RI-28, a radiation-induced T cell leukemia of the CBA/H strain acquired reduced levels of fluorescence-detected natural antibodies from the serum of X-linked immunodeficiency-bearing CBA/N and male (CBA/N x CBA/J) F1 mice compared with the serum from normals. Threshold s.c. inocula of the RI-28 appeared sooner and produced higher tumor frequencies in the X-linked immunodeficiency-bearing animals. This data coupled with the lack of correlating deficiencies in natural killer cell or activated macrophage activity provide the first genetic evidence for the hypothesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785560

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Natural antibody-induced intracellular signalling and growth control in C3H 10T1/2 fibroblast variants.

Authors:  H Wang; D A Chow
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  The molecular basis for a polyspecific antibody.

Authors:  M G Wing
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

3.  CD5+ B cells and naturally occurring autoantibodies in cancer patients.

Authors:  R Stein; I P Witz; J Ovadia; D M Goldenberg; I Yron
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

4.  Tumour cell binding by a human monoclonal IgM antibody from the spleen of a non-tumour-associated patient is due to somatic mutations in the VH gene.

Authors:  J Bohn; B Niemann; D Roggenbuck; W Döcke; S Jahn
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.